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Streptomycin-Induced Inflammation Enhances Escherichia coli Gut
Colonization Through Nitrate Respiration
Alanna M. Spees, Tamding Wangdi, Christopher A. Lopez, Dawn D. Kingsbury, Mariana N. Xavier, Sebastian E. Winter,
Renée M. Tsolis, Andreas J. Bäumler
Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, Davis, California
ABSTRACT Treatment with streptomycin enhances the growth of human commensal Escherichia coli isolates in the mouse intes-
tine, suggesting that the resident microbial community (microbiota) can inhibit the growth of invading microbes, a phenome-
non known as “colonization resistance.” However, the precise mechanisms by which streptomycin treatment lowers coloniza-
tion resistance remain obscure. Here we show that streptomycin treatment rendered mice more susceptible to the development
of chemically induced colitis, raising the possibility that the antibiotic might lower colonization resistance by changing mucosal
immune responses rather than by preventing microbe-microbe interactions. Investigation of the underlying mechanism re-
vealed a mild inflammatory infiltrate in the cecal mucosa of streptomycin-treated mice, which was accompanied by elevated ex-
pression of Nos2, the gene that encodes inducible nitric oxide synthase. In turn, this inflammatory response enhanced the lumi-
nal growth of E. coli by nitrate respiration in a Nos2-dependent fashion. These data identify low-level intestinal inflammation as
one of the factors responsible for the loss of resistance to E. coli colonization after streptomycin treatment.
IMPORTANCE Our intestine is host to a complex microbial community that confers benefits by educating the immune system and
providing niche protection. Perturbation of intestinal communities by streptomycin treatment lowers “colonization resistance”
through unknown mechanisms. Here we show that streptomycin increases the inflammatory tone of the intestinal mucosa,
thereby making the bowel more susceptible to dextran sulfate sodium treatment and boosting the Nos2-dependent growth of
commensal Escherichia coli by nitrate respiration. These data point to the generation of alternative electron acceptors as a by-
product of the inflammatory host response as an important factor responsible for lowering resistance to colonization by faculta-
tive anaerobic bacteria such as E. coli.
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Human isolates of Escherichia coli are generally poor colonizersof the murine gastrointestinal tract, but robust growth in the
large intestine is observed in streptomycin-treatedmice (1, 2). The
streptomycin-treated mouse model has been used widely to study
whether the elaboration of smooth lipopolysaccharide (3, 4), at-
tachment mediated by fimbriae (5–8), motility (9), and the utili-
zation of certain nutrients and trace elements (10–17) are proper-
ties important for the in vivo growth of commensal E. coli. It also
provides a model to study carbon utilization (14, 16, 18–20) and
the role of Shiga-like toxin (21–26) during infection with entero-
hemorrhagic E. coli. However, the mechanism by which strepto-
mycin treatment promotes colonization with E. coli remains elu-
sive.
Marjorie Bohnhoff and coworkers first introduced the concept
that microbial communities in the intestine (the microbiota) can
inhibit the growth of invading pathogens by conferring “coloni-
zation resistance” after noticing that the intestinal tracts of mice
pretreatedwith streptomycin becomehighly susceptible to Salmo-
nella enterica serovar Enteritidis infection (27, 28). Pretreatment
of mice with streptomycin enhances the luminal growth of S. en-
terica serovar Typhimurium (S. Typhimurium) in the murine ce-
cum by lowering colonization resistance (29). In addition, the
antibiotic exacerbates the severity of S. Typhimurium-induced
colitis (30). The enhanced severity of colitis in streptomycin-
treated mice infected with S. Typhimurium has been ascribed to a
decreased “immune resistance,” a term coined recently to describe
specific host-commensal interactions associated with coloniza-
tion resistance that confer protection against mucosal damage
(31). Streptomycin treatment is proposed to reduce colonization
resistance by lowering growth competition between the microbi-
ota and incoming S. Typhimurium (32). Interestingly, conditions
that lower the resistance to colonization by commensal E. coli also
lower immune resistance to S. Typhimurium-induced colitis (33),
but the identities of factors that contribute to these phenomena
are obscure.
Here we describe the identification and characterization of one
of the mechanisms responsible for loss of resistance to E. coli col-
onization after streptomycin treatment.
RESULTS
Streptomycin treatment lowers immune resistance to infectious
and noninfectious colitis. Pretreatment of mice with streptomy-
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cin (a single dose of 20 mg/animal) enhances the susceptibility of
mice to the development S. Typhimurium-induced colitis (30)
(Fig. 1A), presumably because the antibiotic lowers growth com-
petition between themicrobiota and the incoming pathogen (32).
Should streptomycin enhance inflammation because it lowers
microbe-microbe interactions that limit pathogen growth, the an-
tibiotic would not be expected to increase the susceptibility of
mice to the development of colitis caused by exposure to chemi-
cals. To test this prediction, mice received a subpathological con-
centration of dextran sulfate sodium (DSS) in their drinkingwater
(1%) for 8 days. Four days after being switched toDSS-containing
drinking water, some mice were treated with streptomycin (a sin-
gle dose of 20 mg/animal) and their ceca were collected 96 h later.
Treatment of mice with streptomycin and/or 1% DSS did not
result in significant weight loss (see Table S1 in the supplemental
material). Drinking water containing a subpathological concen-
tration of DSS did not induce marked gut inflammation in mice
that were not treated with streptomycin (Fig. 2A), which was con-
sistent with a previous report of a study that used this dose to
identify conditions that exaggerate susceptibility toDSS (34). Sur-
prisingly, streptomycin-treated mice that received a subpatho-
logical concentration of DSS developed mild inflammation, as
indicated by a significantly (P  0.01) increased histopathology
score in the cecum (P 0.05) (Fig. 2A). Thus, in addition to the
known enhancement of the susceptibility to S. Typhimurium-in-
duced colitis (30), these data suggest that streptomycin treatment
also lowers immune resistance to DSS-induced mucosal damage.
Collectively, these data suggest that streptomycin treatment
makes the bowel generally more irritable. Importantly, while it is
conceivable that inhibition of pathogen growth by microbe-
microbe interactions, such as competition for nutrients or meta-
bolic exclusion, explains the enhanced susceptibility of
streptomycin-treated mice to the development of S. Typhimu-
rium-induced colitis, these potential mechanisms did not provide
a compelling explanation for the increased susceptibility of
streptomycin-treated mice to DSS-induced colitis.
Streptomycin treatment increases the inflammatory tone of
the cecal mucosa. Interestingly, we noted that sections of the cecal
mucosa collected from mice treated with streptomycin, followed
by inoculation with sterile medium (LB broth), exhibited mild
FIG 1 Streptomycin treatment is associated with a modest increase in the severity of histopathological changes. Mice received streptomycin or remained
untreated. One day later, mice were inoculated with sterile medium (LB) or infected with S. Typhimurium. Three days after infection, their ceca were collected
for analysis. (A) A veterinary pathologist performed blinded scoring of hematoxylin-eosin-stained sections of the cecal mucosa for histopathological changes.
Each bar represents the combined histopathology score of one individual animal. The statistical significances of differences between groups are indicated above
the brackets. (B) Representative images of sections from mice receiving LB (left) or LB plus streptomycin (middle and right). Arrows indicate mild diffuse
inflammatory infiltrates in the lamina propria (right). A focal inflammatory infiltrate in the cecal mucosa is shown in the dashed square, and a larger magnifi-
cation of this region is presented in the inset. Mono, monocyte; PMN, polymorphonuclear neutrophil.
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inflammatory changes, unlike those from mice inoculated with
sterile medium alone (P  0.05) (Fig. 1A). These inflammatory
changes includedmild diffuse inflammatory infiltrates in the lam-
ina propria and occasional focal infiltrates in themucosa (Fig. 1B).
To further investigate possible inflammatory changes induced by
streptomycin treatment, we next analyzed the composition of cells
present in the cecal mucosa by using flow cytometry.
Mice were treated with streptomycin (a single dose of 20 mg/
animal) and sterile medium (LB broth) or with sterile medium
alone, and a single-cell suspension was generated from the cecum
96 h later. After doublet elimination and exclusion of dead cells
(dead/live aqua staining), live cecal cells were gated for a popula-
tion that was negative for the T cell marker CD3 (cluster of differ-
entiation 3), the B cell marker B220, and the NK/NKT cell marker
NK1.1. Inflammatory phagocytes present in the CD3 B220
NK1.1 population were identified as cells expressing CD11B, a
chain of CR3 (complement receptor 3), and Ly6C (lymphocyte
antigen 6 complex, locus C), a marker expressed by neutrophils
and inflammatory monocytes but absent from tissue-resident
macrophages and tissue-resident dendritic cells (Fig. 3A). Finally,
CD3 B220 NK1.1 CD11B Ly6C phagocytes were further
differentiated into neutrophils and monocytes on the basis of the
expression of the neutrophil marker Ly6G (Fig. 3B). The Ly6G/
Ly6C markers are superior to Gr-1 (granulocyte differentiation
antigen 1) for the identification of neutrophils/monocytes, and
previous work suggests that the mouse macrophage marker F4/80
is not required for the identification of these subsets (35).
Remarkably, streptomycin treatment significantly (P  0.01)
increased the fraction of live cecal cells that expressed markers of
inflammatory monocytes (i.e., CD3 B220 NK1.1 CD11B
Ly6C Ly6G cells) (Fig. 3C). Furthermore, streptomycin treat-
ment was associated with a significant (P  0.01) increase in the
fraction of neutrophils (i.e., CD3 B220 NK1.1 CD11B
Ly6C Ly6G cells) present within the live cecal cell suspension
(Fig. 3B and D). In contrast, the number of resident phagocytes
(i.e., CD3 B220NK1.1 CD11B Ly6C Ly6G cells) present
in the live cecal cell population remained unchanged after strep-
tomycin treatment (Fig. 3E). We next repeated the experiment to
monitor inflammatory changes at later time points after strepto-
mycin treatment. The results revealed that the infiltrates of in-
flammatory monocytes (Fig. 3F) and neutrophils (Fig. 3G) were
relatively short-lived, because the fraction of both cell types in live
cecal cell suspensions returned to background levels within
15 days after streptomycin treatment.
Collectively, our results suggested that a single dose of strepto-
mycin increased the inflammatory tone of the cecal mucosa tem-
porarily, which was characterized by an infiltrate with neutrophils
and inflammatory monocytes that peaked a few days after antibi-
otic treatment.
Streptomycin induces colitis in mice treated with a sub-
pathological concentration of DSS. We next analyzed phagocyte
populations in mice treated with a subpathological concentration
of DSS by using flow cytometry, because this method provides a
higher resolution for the characterization of mild inflammatory
changes than histopathology scoring does (Fig. 2A).
Streptomycin-treatedmice (a single dose of 20mg/animal) receiv-
ing a subpathological concentration of DSS (1%) harbored signif-
icantly (P  0.05) greater fractions of inflammatory monocytes
(Fig. 2B) and neutrophils (Fig. 2C) in their live cecal cell popula-
tion than didmice receiving streptomycin alone ormice receiving
a subpathological concentration of DSS alone. These results fur-
ther corroborated our observation that streptomycin treatment
lowers immune resistance to DSS-induced mucosal damage
(Fig. 2A).
Streptomycin-treated mice exhibit a marked increase in mu-
cosal Nos2 expression. To start investigating whether there is a
mechanistic link between streptomycin-induced inflammation
and reduced resistance to E. coli colonization, we determined
whether streptomycin treatment (a single dose of 20 mg/animal)
altered the expression of inflammatory markers in the cecal mu-
cosa by quantitative real-time PCR (Fig. 4). Streptomycin treat-
ment resulted in a modest increase in mRNA levels of Kc (also
known as Cxcl1) (Fig. 4A), which encodes the neutrophil che-
moattractant KC (keratinocyte-derived cytokine), andMip2 (also
known as Cxcl2) (Fig. 4B), which encodes the neutrophil che-
moattractant MIP2 (macrophage inflammatory protein 2), but
FIG 2 Streptomycin induces colitis in mice treated with a subpathological concentration of DSS. Mice were housed normally or received drinking water
supplementedwith 1%DSS. Four days after the beginning ofDSS treatment, somemice received a single dose of streptomycin and their cecawere collected 4 days
later for analysis. (A) A veterinary pathologist performed blinded scoring of hematoxylin-eosin-stained sections of the cecal mucosa for histopathological
changes. Boxes inwhisker plots represent the second and third quartiles of combined histopathology scores, while lines indicate the first and fourth quartiles. The
number of animals (N) in each group is indicated at the bottom. (B and C) Analysis of cecal cell suspensions from at least four animals per group was performed
by flow cytometry. Bars represent the geometric means the standard errors of the numbers of inflammatory monocytes (B) and neutrophils (C) expressed as
percentages of the total number of live cecal cells (A to C). The statistical significances of differences between groups are indicated above the bars.
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these differences did not reach statistical significance. There was a
small but significant (P 0.05) increase in mRNA levels ofMcp1
(also known as Ccl2) (Fig. 4C), which encodes MCP-1 (monocyte
chemoattractant protein 1), and Mcp2 (also known as Ccl8)
(Fig. 4D), which encodes MCP-2, after streptomycin treatment.
The small increases in the expression of genes that encode che-
moattractants that were observed after streptomycin treatment
were consistent with themild infiltrate of neutrophils (Fig. 3B and
D) and inflammatory monocytes (Fig. 3C) detected in live cecal
cell suspensions.
Next, we investigated the expression of other genes whose
mRNA levels are markedly increased during intestinal inflamma-
tion (36, 37), including Lcn2, which encodes the antimicrobial
protein lipocalin-2, and Nos2, which encodes inducible nitric ox-
ide (NO) synthase (iNOS). Consistent with themodest increase in
mRNA levels observed for other markers of inflammation, we
observed a small (3.8-fold) but significant (P  0.01) increase in
the expression of Lcn2 in the cecal mucosa at 1 day after strepto-
mycin treatment (Fig. 4E). Remarkably, levels of Nos2 mRNA
were, on average, 85.6-fold elevated at 96 h after streptomycin
treatment (P 0.01) (Fig. 4F). This marked increase in the abun-
dance ofNos2mRNAwas of particular interest, because iNOS has
recently been implicated in enhanced nitrate production in the
intestinal lumen, thereby enhancing the growth of E. coli through
anaerobic nitrate respiration (38). Thus, analysis of the expression
of genes that encode inflammatory markers suggested a possible
mechanistic link between the streptomycin-induced increase in
Nos2mRNA levels (Fig. 4F) and the reduced resistance of mice to
E. coli colonization.
Streptomycin treatment enhances the growth of E. coli by
nitrate respiration. To test the hypothesis that a streptomycin-
induced increase inNos2mRNA levels fuels the growth ofE. coli in
themurine large intestine by nitrate respiration, we used the com-
mensal E. coli strain Nissle 1917. E. coli possesses three nitrate
reductases encoded by the narGHJI, narZYWV, and napFD-
AGHBC operons (39). Inactivation of the narG, napA, and narZ
genes in E. coli Nissle 1917 resulted in loss of nitrate reductase
activity (Fig. 5A). Tomimic the growth conditions in the lumen of
FIG 3 Streptomycin treatment elicits infiltrates of inflammatory monocytes and neutrophils in the cecal mucosa. (A) Gating strategy for analysis of cecal cell
suspensions. After doublet elimination (top right), live cells were gated (top left) and CD3 B220 NK1.1 cells were eliminated by using a dump channel
(bottom left). CD3 B220 NK1.1 cells were then analyzed for CD11B and Ly6C expression (bottom right). (B) CD3 B220 NK1.1 CD11B Ly6C
phagocytes were separated into Ly6G cells (inflammatory monocytes) and Ly6G cells (neutrophils) (C to G). Bars represent the geometric means  the
standard errors of the numbers of inflammatory monocytes (C and F), neutrophils (D and G), and resident phagocytes (E) expressed as percentages of the total
number of live cecal cells (C to E). The statistical significance of the difference between groups is indicated at the top of each graph. NS, not statistically
significantly different. For panels A to E, the ceca of groups of mice (n 9) were collected 4 days after streptomycin treatment, and for panels F and G, the ceca
of groups of mice (n 3) were collected 4 (black bars), 10 (gray bars), or 15 (white bars) days after streptomycin treatment.
Spees et al.
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the large bowel, mucin broth (i.e., hog mucin dissolved in a buff-
ered solution) was inoculated with an equal mixture of
streptomycin-resistant E. coli Nissle 1917 (CAL225) and a nitrate
respiration-deficient narG napA narZ triple mutant (CAL222)
and incubated overnight anaerobically. The two strains were re-
covered in equal numbers after anaerobic growth in mucin broth,
suggesting that inactivation of the narG, napA, and narZ genes did
not impair the growth of E. coli in the absence of nitrate. However,
the nitrate respiration-deficient narG napA narZ triple mutant
was outcompeted by the wild-type strain during competitive an-
aerobic growth in mucin broth supplemented with nitrate (P 
0.001) (Fig. 5B). These and previous data (17) suggest that nitrate
respiration confers a fitness advantage upon E. coli under growth
conditions that mimic those encountered in the large intestine.
We next investigated whether streptomycin treatment confers
a growth advantage upon E. coli in the mouse large intestine.
Groups of mice were inoculated with streptomycin (a single dose
of 20mg/animal) or left untreated and were inoculated 1 day later
with an equalmixture of streptomycin-resistant E. coliNissle 1917
(CAL225) and an isogenic nitrate respiration-deficient narG napA
narZ triple mutant (CAL222). In the absence of streptomycin
treatment, the wild type and the narG napA narZ mutant colo-
nized the mouse intestine poorly and were recovered in equal
numbers from the feces (Fig. 5C) and colon contents (Fig. 5D). In
contrast, the wild-type strain was recovered in significantly (P 
0.005) higher numbers than the narG napA narZ mutant from
streptomycin-treated mice 6 days after infection (Fig. 5D). These
data suggested that nitrate respiration conferred a fitness advan-
tage in the large intestines of streptomycin-treated mice but not
during growth in the intestines of conventional mice. Further-
more, the overall numbers of E. coli bacteria recovered from the
colon contents of streptomycin-treated mice were significantly (P
 0.01) higher than those recovered from untreated control mice
(Fig. 5E), illustrating the colonization resistance-lowering effect of
streptomycin. Nitrate respiration accounted for only part of this
difference, pointing to the existence of additional mechanisms
that contribute to the loss of colonization resistance after treat-
ment with streptomycin.
Finally, wewanted to test whether there is a causal link between
the streptomycin-induced increase inNos2mRNA levels (Fig. 4F)
and the streptomycin-induced growth of E. coli by nitrate respira-
tion. To this end, we inoculated groups of Nos2-deficient mice
with streptomycin or left them untreated and inoculated them 1
day later with an equal mixture of streptomycin-resistant E. coli
Nissle 1917 (CAL225) and an isogenic narG napA narZ mutant
(CAL222). Remarkably, the wild type and the narG napA narZ
mutant were recovered in equal numbers from the colon contents
of Nos2-deficient mice, regardless of streptomycin treatment
(Fig. 5D). These data suggested that the fitness advantage con-
ferred by nitrate respiration in streptomycin-treated mice was
Nos2 dependent, thereby providing a causal link between
FIG 4 Streptomycin treatment markedly enhances mucosal Nos2mRNA levels. Groups of mice (n 4) were mock treated (LB) or streptomycin treated (LB
plus streptomycin), and RNA was extracted from their ceca 1 or 4 days after inoculation. Transcript levels of Cxcl1 (A), Cxcl2 (B), Ccl2 (C), Ccl8 (D), Lcn2 (E),
andNos2 (F) were determined by quantitative real-time PCR. Bars represent the geometric means the standard errors of n-fold changes inmRNA levels of the
streptomycin-treated group versus themock-treated group at each time point. The statistical significance of differences between groups is indicated at the top of
each graph. NS, not statistically significantly different.
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streptomycin-induced inflammation and the enhanced growth of
(i.e., loss of resistance to colonization by) E. coli.
DISCUSSION
It is known that conditions of intestinal inflammation can lead to
a microbial imbalance (dysbiosis) in the intestine that is charac-
terized by a marked decrease in the representation of obligate
anaerobic bacteria (i.e., members of the classes Bacteroidia and
Clostridia) and an increased relative abundance of facultative an-
aerobic bacteria, which are commonly members of the family En-
terobacteriaceae (reviewed in reference 40). In other words, intes-
tinal inflammation is a known mechanism of reducing resistance
to colonization by Enterobacteriaceae. However, since no overt
inflammatory changes are detected as a consequence of treating
mice with streptomycin (30, 41, 42), elimination of microbe-
microbe interactions is commonly considered amore likely expla-
nation for the associated loss of resistance to E. coli colonization.
Specifically, streptomycin treatment is assumed to reduce the col-
onization resistance of mice because the antibiotic kills microbes
that prevent colonization by incoming human E. coli isolates by
metabolic exclusion or competition for nutrients, thereby freeing
an otherwise occupied niche (reviewed in reference 31). This hy-
pothesis suggests that colonization resistance is defined as the
presence of a factor, namely, the presence of certainmicrobes that
successfully compete with E. coli. In contrast, results presented
here support the alternative view that colonization resistance is
defined, at least in part, as the absence of a factor, namely, the
absence of intestinal inflammation.
Our data suggest that streptomycin reduces colonization resis-
tance, at least in part, by generating amild inflammatory response
that supports the growth of E. coli through nitrate respiration,
thereby generating a new niche rather than clearing an existing
niche of competitors. Inflammation induces the expression of
iNOS (43), an enzyme that generates NO (44). NO can react with
superoxide radicals produced during inflammation to yield per-
oxynitrite (ONOO) (45), which can be converted to nitrate
(NO3) (46). Nitrate respiration enhances the growth of com-
mensalE. coli inmicewithDSS-induced colitis. In contrast, iNOS-
deficient mice with DSS-induced colitis or normal mice that lack
intestinal inflammation do not support the growth of E. coli by
nitrate respiration (40). These data suggest that a by-product of
intestinal inflammation is the generation of alternative electron
acceptors, such as nitrate, that support the growth of E. coli and
other members of the family Enterobacteriaceae by anaerobic res-
FIG 5 Streptomycin boosts the Nos2-dependent growth of E. coli through nitrate respiration. (A) Nitrate reductase activities of E. coli Nissle 1917 (wild type)
and an isogenic nitrate respiration-deficient mutant (narG napA narZmutant). (B) Competitive anaerobic growth of the wild type and narG napA narZmutant
in mucin broth in the presence () or absence () of 40 mM nitrate. (C) Competitive indices (CI) of the wild type and the narG napA narZmutant recovered
over time from feces of streptomycin-pretreatedmice (black squares) or untreatedmice (open circles). (D)Competitive indices (CI) of thewild type and thenarG
napA narZ mutant recovered from the colon contents of wild-type mice (C57BL/6) or Nos2-deficient mice 6 days after infection (B to D). Data represent the
geometric means the standard errors of competitive indices (CI) of the wild type and the narG napA narZmutant. (E) Absolute numbers of wild-type (black
bars) and narG napA narZ mutant (white bars) E. coli CFU recovered from colon contents. The magnitudes of nitrate respiration-dependent and nitrate
respiration-independent contributions to colonization resistance are indicated on the right. A dashed line indicates the limit of detection. (A, B, D, and E) The
statistical significance of differences between groups is indicated at the top of each graph. NS, not statistically significantly different.
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piration (38, 47, 48). Anaerobic respiration enables facultatively
anaerobic bacteria to utilize nonfermentable carbon sources,
thereby sidestepping the competitionwith obligate anaerobic bac-
teria that rely on the fermentation of carbohydrates and amino
acids for growth (49). Through this mechanism, anaerobic respi-
ration provides E. coli with a fitness advantage during growth in
the inflamed intestine (38). Conversely, the absence of this fitness
advantage in the healthy gut is manifested as resistance to E. coli
colonization.
The unexpected identification of intestinal inflammation as
one of the mechanisms by which streptomycin treatment reduces
colonization resistance puts the spotlight on a previously un-
known consequence of using this antibiotic. That is, how does
streptomycin treatment induce themild inflammatory changes in
the cecal mucosa that ultimately drive bacterial growth by nitrate
respiration? An increased inflammatory tone of the intestinal mu-
cosa following antibiotic therapy is notwithout precedent, asmice
exhibit increased macrophage and NK cell infiltration in the in-
testinal mucosa after oral metronidazole treatment (42). How-
ever, the elucidation of underlying mechanisms is complicated
because factors that confer immune resistance to intestinal in-
flammation are not identical to those that enhance resistance to
colonization by Enterobacteriaceae. For example, the abundance
within themicrobial community of bacteria belonging to the fam-
ily Porphyromonadaceae (phylum Bacteroidetes) correlates with
protection against S. Typhimurium-induced colitis (i.e., with in-
creased immune resistance) but does not affect the growth of the
pathogen in the intestinal lumen (i.e., it does not alter coloniza-
tion resistance) (50). Our finding that streptomycin lowers im-
mune resistance to DSS-induced colitis is of interest because the
onset of irritable bowel syndrome, a condition characterized by
low-level intestinal inflammation and diarrhea, often follows sur-
gery or repeated courses of antibiotics (reviewed in reference 51).
Thus, the streptomycin-treated mouse might be a model of hu-
man irritable bowel syndrome rather than a model of the healthy
human gut.
Interestingly, transfer of a normal complex microbiota can re-
store the resistance of mice to colonization by S. Typhimurium
(52). Consistent with a possible role for microbiota-induced mu-
cosal responses in mediating colonization resistance, intestinal
bacteria and their metabolic by-products are known to directly
impact the repertoire and activity of intestinal immune cells (53–
57). However, previous metagenomic studies did not succeed in
establishing a correlation between reduced colonization resistance
induced by antibiotic treatment and a decreased abundance of a
specific bacterial species or family within the microbial commu-
nity (32, 41, 50, 52). As a result, the identification of microbiota-
host interactions underlying colonization resistance remains an
important challenge for future research.
MATERIALS AND METHODS
Bacterial strains and culture conditions. S. Typhimurium strain IR715
(58) is a fully virulent, nalidixic acid-resistant derivative of wild-type iso-
late ATCC 14028 (American Type Culture Collection). Bacteria were cul-
tured overnight aerobically at 37°C in Luria-Bertani (LB) broth or on LB
plates (15 g/liter agar) with the appropriate antibiotics at the following
concentrations: nalidixic acid, 0.05mg/ml; carbenicillin, 0.1mg/ml; kana-
mycin, 0.1 mg/ml.
Plasmid construction. E. coli strains used for mouse infections con-
tained a streptomycin resistancemarker to facilitate recovery. To this end,
a streptomycin resistance cassette () was isolated by digesting plasmid
pHP45 (59)with the restriction enzymeBamHI (NewEnglandBiolabs).
The  cassette was then inserted into the BamHI site of pWSK29 or
pWSK129 (60) via ligation to yield plasmid pCAL62 or pCAL61, respec-
tively. Plasmid pCAL62was transformed into wild-type E. coliNissle 1917
(61) to create CAL225, and plasmid pCAL61 was transformed into the
isogenic napA narZ narGmutant (SW930) (38) to yield CAL222.
Competitive-growth assays. For competition assays, bacteria were
grown inmucinmediumcontaining 0.25% type II porcinemucin (Sigma-
Aldrich), 40 mMmorpholinepropanesulfonic acid buffer, trace elements
(62), and magnesium sulfate (265 mg/liter) dissolved in sterile water.
Either sterile water as a negative control or 40mMsodiumnitrate (Sigma-
Aldrich) was added to the medium immediately prior to inoculation with
a 1:1 ratio of CAL225 andCAL222 at a total concentration of 105 CFU/ml.
Bacteria were allowed to grow anaerobically for 16 h at 37°C (Bactron I
anaerobic chamber; Sheldon Manufacturing, Cornelius, OR), and then
the ratio of the two strains was determined by spreading serial 10-fold
dilutions on LB agar plates containing the appropriate antibiotics. In vitro
competition assays were performed in triplicate with cultures inoculated
from different colonies. The competitive index was calculated by dividing
the number of bacteria carrying the wild-type allele by the number of
bacteria with the respective mutant allele and corrected by the ratio of
these strains in the inoculum.
Nitrate reductase activity assay. Overnight cultures of E. coli strains
were diluted 1:50 in fresh LB broth supplemented with 40 mM sodium
nitrate. Cultures were statically incubated for 3 h at 37°C, and the relative
nitrate reductase activity was measured as described previously (63).
Briefly, the nitrate reductase assay measures the reduction of nitrate to
nitrite with methyl viologen as the electron donor. Nitrate is added to the
reactionmedium containing lysed bacterial cells, and nitrite (from nitrate
reductase activity) is measured on the basis of its formation of a colored
azo compound, which is quantified with a spectrophotometer. Assays
were performed in triplicate with different colonies.
Animal experiments. All animal experiments were approved by the
Institutional Animal Care and Use Committee at the University of Cali-
fornia, Davis, and performed according to Association for Assessment
and Accreditation of Laboratory Animal Care guidelines. Female 10- to
12-week-old C57BL/6 mice (The Jackson Laboratory) or Nos2-deficient
mice (stock no. 2609; The Jackson Laboratory) were used for mouse ex-
periments. In brief, mice were inoculated intragastrically with streptomy-
cin (0.1 ml of a 200-mg/ml solution in distilled water) as described previ-
ously (30). For infected groups, 24 h later, mice were inoculated
intragastrically either with sterile LB broth or with bacteria (0.1 ml con-
taining approximately 1 109CFU/ml). At the indicated timepoints after
infection, mice were euthanized and samples of their ceca were collected
for the isolation ofmRNA, for histopathological analysis, or for collection
of cells. For bacteriologic analysis, cecal contents, colon contents, or fecal
pellets were collected at the indicated time points and homogenized and
serial 10-fold dilutions were spread on agar plates containing the appro-
priate antibiotics. For low-level DSS experiments, mice were given 1%
DSS salt (catalogue no. 160110; MP Biomedicals) in their drinking water
continuously for 8 days as described previously (34). DSS was replaced
with fresh DSS solution every 2 to 3 days during this time.Mice were then
inoculated with streptomycin at day 4 of DSS treatment as described
above. Mouse body weights were determined daily.
Quantitative real-time PCR. Transcript levels of murine genes in
RNA isolated from the cecal mucosa were determined as described previ-
ously (36). For quantitative analysis of mRNA levels, 1 g of RNA from
each sample was reverse transcribed in a 50-l volume (TaqMan reverse
transcription reagent; Applied Biosystems), and 4 l of cDNA was used
for each real-time reaction. Real-time PCR was performed with Sybr
green (Applied Biosystems) and a 7900HT fast real-time PCR system. The
data were analyzed by a comparative cycle threshold method (Applied
Biosystems). Increases in cytokine expression in infected mice were cal-
culated relative to the average level of the respective cytokine in four
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control animals from the corresponding time point. A list of the genes
analyzed in this study with the respective primers is provided in Table 1.
Histopathology. Tissue samples were fixed in formalin, processed ac-
cording to standard procedures for paraffin embedding as described pre-
viously (36), sectioned at 5 m, and stained with hematoxylin and eosin.
A veterinary pathologist scored inflammatory changes by blind sample
analysis. Neutrophil and monocyte counts were determined by high-
magnification (400) microscopy, and numbers of cells in 10 micro-
scopic fields were averaged for each animal.
Isolation of intestinal lymphocytes. The isolation of intestinal lym-
phocytes for experiments has been described previously (64). To isolate
cecal lymphocytes for measurements of in vivo cellular analysis, control
and experimental mouse groups were sacrificed at the designated time
points. The cecum and proximal colon were collected, and fat and con-
nective tissue were removed. Intestinal sections were cut longitudinally
from the proximal colon to the tip of the cecum. The cecal content was
removed by gentle scrapingwith the flat edge of scissors. The sectionswere
subsequently washed in cold 1Hanks balanced salt solution (catalogue
no. 14185; Gibco) containing 0.015 M HEPES (catalogue no. 15630;
Gibco) a total of six times to remove mucus and remaining fecal matter.
To isolate lymphocytes, the tissue was added to 10 ml of prewarmed
(37°C) 1 RPMI (Sigma catalogue no. R1145) containing 10% fetal bo-
vine serum, 1% penicillin-streptomycin (catalogue no. 15240-062;
Gibco), 0.015 M HEPES, and 0.010 M glutamine. Additionally, collage-
nase digestive units (furylacryloyl-leucine-glycyl-propyl-alanine) (Lib-
erase, catalogue no. 05401127001; Roche) at 2.9U/ml and 300UofDNase
(Roche catalogue no. 04716728001) were added to the medium. The tis-
sue was then processed with a GentleMACS tissue disruptor according to
a protocol provided by the manufacturer (Miltenyi).
Flow cytometry. The analysis of surface marker expression in intesti-
nal lymphocytes (C57BL/6; The Jackson Laboratory) has been described
previously (64). In brief, a total of 4  106 intestinal cells were resus-
pended in 2 ml Dulbecco’s phosphate-buffered saline (PBS) without cal-
cium and magnesium and stained with aqua live/dead cell discriminator
(no. L34597; Invitrogen) in accordance with themanufacturer’s protocol.
Cells were then rinsed and resuspended in 50 l fluorescence-activated
cell sorting (FACS) buffer (PBS containing 1%bovine serumalbumin and
1 mM EDTA). Four microliters of the anti-CD16/32 blocking antibody
(clone 93; eBioscience) was added to each sample. Cells were then stained
for 20min in the dark at 4°Cwith optimized concentrations of anti-CD3–
phycoerythrin (PE) (clone 17A2; eBioscience), anti-B220–PE (clone
RA3-6B2; eBioscience), anti-NK1.1–PE (eBioscience clone PK136), anti-
Ly6C–Pacific Blue (clone HK1.4; eBioscience), anti-Ly6G–PerCP Cy5.5
(clone 1A8; BD Pharmingen), and anti-CD11b–allophycocyanin Cy7
(cloneM1/70; BioLegend) antibodies. Cells were washed twice with FACS
buffer and subsequently fixed in 4% paraformaldehyde for 1 h. Cells were
then washed twice and resuspended in FACS buffer and analyzed with an
LSR II flow cytometer (Becton Dickinson, San Jose, CA). The data were
analyzed by using FlowJo software (TreeStar, Inc., Ashland, OR). Gates
were set on singlets and then on live cells. Subsequent gates were based on
fluorescence minus one and unstained controls.
Statistical analysis. To determine the statistical significance of differ-
ences between treatment groups in the animal experiments, an unpaired
Student t test was used. A P value of less than 0.05 was considered to be
significant.
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